From: Effectiveness of first-line antiretroviral therapy in the IPEC cohort, Rio de Janeiro, Brazil
 |  | 12 months | 24 months | ||
---|---|---|---|---|---|
 |  | Unadjusted | Adjusted | Unadjusted | Adjusted |
 |  | RR (95% CI) | RR (95% CI) | RR (95% CI) | RR (95% CI) |
Age | |||||
 | < 30 | Ref. |  | Ref. | Ref. |
 | 30-39 | 0.99 (0.91, 1.08) |  | 1.05 (0.93, 1.18) | 1.06 (0.94, 1.19) |
 | > = 40 | 1.04 (0.95, 1.13) |  | 1.09 (0.98, 1.22) | 1.12 (1.00, 1.26) |
Race | |||||
 | Non-white | Ref. |  | Ref. |  |
 | White | 1.07 (1.00, 1.14) |  | 1.05 (0.97, 1.15) |  |
Gender/Risk category a | |||||
 | Women | 0.89 (0.82, 0.98) | 0.90 (0.82, 0.99) | 0.92 (0.82, 1.03) | 0.94 (0.84, 1.06) |
 | Heterosexual men | Ref. | Ref. | Ref. | Ref. |
 | MSM | 1.05 (0.97, 1.15) | 1.02 (0.93, 1.12) | 1.11 (0.99, 1.25) | 1.11 (0.98, 1.25) |
 | IDU/Other | 1.02 (0.90, 1.16) | 1.02 (0.89, 1.16) | 0.93 (0.78, 1.11) | 0.95 (0.79, 1.13) |
Education | |||||
 | < 4 years | Ref. | Ref. | Ref. | Ref. |
 | 4-8 years | 1.06 (0.96, 1.17) | 1.07 (0.96, 1.18) | 1.12 (0.98, 1.28) | 1.13 (0.99, 1.29) |
 | > 8 years | 1.16 (1.06, 1.27) | 1.13 (1.03, 1.24) | 1.17 (1.04, 1.32) | 1.14 (1.00, 1.29) |
Years since HIV + test | |||||
 | <= 3 | Ref. |  | Ref. |  |
 | > 3 | 0.97 (0.90, 1.04) |  | 0.94 (0.86, 1.03) |  |
Baseline CD4 cell count b | |||||
 | <= 200 | Ref. |  | Ref. |  |
 | 201-350 | 1.05 (0.97, 1.14) |  | 1.01 (0.91, 1.12) |  |
 | > 350 | 1.09 (0.99, 1.20) |  | 1.11 (0.97, 1.26) |  |
 | Missing | 0.92 (0.83, 1.03) |  | 1.01 (0.88, 1.15) |  |
Baseline HIV viral load c | |||||
 | <= 100000 | Ref. |  | Ref. |  |
 | > 100000 | 1.00 (0.93, 1.08) |  | 1.03 (0.93, 1.14) |  |
 | Missing | 0.95 (0.87, 1.04) |  | 0.99 (0.88, 1.11) |  |
Concurrent ADI d | |||||
 | No | Ref. |  | Ref. |  |
 | Yes | 1.06 (0.98, 1.16) |  | 1.06 (0.95, 1.18) |  |
Hepatitis B/C co-infection e | |||||
 | No | Ref. |  | Ref. |  |
 | Yes | 1.16 (0.95, 1.43) |  | 1.07 (0.83, 1.39) |  |
Initial ART regimen f | |||||
 | PI-based | Ref. |  | Ref. | Ref. |
 | NNRTI-based | 1.04 (0.96, 1.13) |  | 1.20 (1.08, 1.34) | 1.17 (1.05, 1.31) |
Calendar year of ART initiation | |||||
 | 2005-2010 | 1.28 (1.18, 1.39) | 1.25 (1.15, 1.35) | 1.20 (1.09, 1.33) | 1.14 (1.03, 1.27) |
 | 2000-2004 | Ref. | Ref. | Ref. | Ref. |
Started ART in clinical trial | |||||
 | No | Ref. | Ref. | Ref. | Ref. |
 | Yes | 1.10 (1.03, 1.18) | 1.08 (1.01, 1.16) | 1.14 (1.04, 1.25) | 1.12 (1.02, 1.23) |